Co-founder, Chairman and CEO of Bionure. MBA.

More than 15 years of professional experience in Healthcare. Senior positions in Strategic Marketing and Business Development. Experience in the Management of academic research: Director of Innovation at the Hospital Clinic de Barcelona, promoting tech transfer and Spin-Offs. Entrepreneur involved in several tech projects. Uses to teach entrepreneur skills in several business schools (EADA, IESE)

Co-founder and CSO of Bionure. MD and PhD in Neuroimmunology.

Strong expertise as a researcher (i.e. UCSF). Director of Neuroimmunology at Hospital Clinic de Barcelona, IDIBAPS. Published >80 scientific articles about the pathogenesis and new therapies for MS. Inventor of 9 patents about the diagnosis and treatment of MS and other brain and retina diseases. Member of several Advisory Boards (Roche, Novartis, Advancell, Neurotec, Digna).

Joaquim Trias Puig-Sureda is one of the top names in the American biotech sector with more than 20 years experience in biotech development at Silicon Valley. He has helped found companies like Microcide Pharmaceuticals, Vicuron (acquired by Pfizer), Peninsula (bought by Johnson&Johnson), Anthera and Tetraphase.

MD Harvard University, NIH Fellow at Harvard Medical School, and currently Professor, Departments of Neurology and Neurological Sciences, Stanford University. Co-Inventor of leading MS drug Natalizumab and several new therapies for autoimmune diseases (eg. DNA vaccination)

MD University of Washington, Professor of Medicine, Neurology, Ophthalmology and Neurosurgery at the University of Washington up until 2004. Currently CMO in an innovation biotech company. Ex-Clinical science Unit Head, Ophthalmology and eHealth Global Strategic Lead, Novartis.

MD Harvard Medical School and currently Professor and Chair, Department of Neurology, UCSF. Dr. Hauser has been appointed by President Obama to the Presidential Commission for the Study of Bioethical Issues.